{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:37:20Z","timestamp":1713919040454},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"DOI":"10.7759\/cureus.58798","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T07:23:17Z","timestamp":1713856997000},"source":"Crossref","is-referenced-by-count":0,"title":["Early Onset of Severe Interstitial Pneumonitis Associated With Anti-PD-1 Immune Checkpoint Antibody After Pleurodesis"],"prefix":"10.7759","author":[{"given":"Sanshiro","family":"Haga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimasa","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TS","year":"2019","unstructured":"Mok TS, Wu YL, Kudaba I, et al.. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019, 393:1819-30. 10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000533302","article-title":"Evaluation of time to onset and outcome of lung adverse events related to pembrolizumab using marketing surveillance","volume":"101","author":"Kanbayashi Y","year":"2023","unstructured":"Kanbayashi Y, Kobayashi M, Anzai M, Shimizu T, Uchida M. Evaluation of time to onset and outcome of lung adverse events related to pembrolizumab using marketing surveillance. Oncology. 2023, 101:817-21. 10.1159\/000533302","journal-title":"Oncology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay M","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, et al.. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017, 50:10.1183\/13993003.00050-2017","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12496","article-title":"Clinical features and survival of lung cancer patients with pleural effusions","volume":"20","author":"Porcel JM","year":"2015","unstructured":"Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015, 20:654-9. 10.1111\/resp.12496","journal-title":"Respirology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2016.04.005","article-title":"A propensity score-matched comparison of the efficacies of OK-432 and talc slurry for pleurodesis for malignant pleural effusion induced by lung adenocarcinoma","volume":"54","author":"Nohara K","year":"2016","unstructured":"Nohara K, Takada K, Kojima E, et al.. A propensity score-matched comparison of the efficacies of OK-432 and talc slurry for pleurodesis for malignant pleural effusion induced by lung adenocarcinoma. Respir Investig. 2016, 54:341-6. 10.1016\/j.resinv.2016.04.005","journal-title":"Respir Investig"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7464","article-title":"Interstitial lung disease after pleurodesis for malignant pleural effusion","volume":"56","author":"Yokoe N","year":"2017","unstructured":"Yokoe N, Katsuda E, Kosaka K, et al.. Interstitial lung disease after pleurodesis for malignant pleural effusion. Intern Med. 2017, 56:1791-7. 10.2169\/internalmedicine.56.7464","journal-title":"Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2017.11.006","article-title":"Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis","volume":"56","author":"Sakata S","year":"2018","unstructured":"Sakata S, Matsuoka Y, Kawahara K, et al.. Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis. Respir Investig. 2018, 56:195-8. 10.1016\/j.resinv.2017.11.006","journal-title":"Respir Investig"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino M","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, et al.. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016, 22:6051-60. 10.1158\/1078-0432.CCR-16-1320","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo J","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, et al.. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2017, 35:709-17. 10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.6.2268","article-title":"Talc and silver nitrate induce systemic inflammatory effects during the acute phase of experimental pleurodesis in rabbits","volume":"125","author":"Marchi E","year":"2004","unstructured":"Marchi E, Vargas FS, Acencio MM, Antonangelo L, Teixeira LR, Genofre EH, Light RW. Talc and silver nitrate induce systemic inflammatory effects during the acute phase of experimental pleurodesis in rabbits. Chest. 2004, 125:2268-77. 10.1378\/chest.125.6.2268","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241225-early-onset-of-severe-interstitial-pneumonitis-associated-with-anti-pd-1-immune-checkpoint-antibody-after-pleurodesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T07:23:21Z","timestamp":1713857001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241225-early-onset-of-severe-interstitial-pneumonitis-associated-with-anti-pd-1-immune-checkpoint-antibody-after-pleurodesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.58798","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}